久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

武漢佰樂(lè)博生物技術(shù)有限公司
   
     
聯(lián)系熱線
  • 聯(lián)系人:方經(jīng)理
  • 電 話:027-65279366
  • 郵箱:products@biolabreagent.com
  • 地 址:武漢市東湖新技術(shù)開(kāi)發(fā)區(qū)神墩四路666號(hào)C棟

武漢佰樂(lè)博代理:Research Grade Lucatumumab

發(fā)表時(shí)間:2023-06-28

武漢佰樂(lè)博代理:Research Grade Lucatumumab  

貨號(hào)DHD68905

產(chǎn)品鏈接:http://www.atagenix.com/product_detail-75458.html

產(chǎn)品購(gòu)買聯(lián)系方式:027-65279366

產(chǎn)品介紹:Lucatumumab (HCD122)是一種全人抗CD40拮抗劑單克隆抗體,可阻斷CD40/ CD40L介導(dǎo)的信號(hào)通路。Lucatumumab可有效介導(dǎo)抗體依賴性細(xì)胞介導(dǎo)的細(xì)胞毒性(ADCC)和腫瘤細(xì)胞清除,可用于頑固性淋巴瘤、慢性淋巴細(xì)胞白血病(CLL)和多發(fā)性骨髓瘤研究。

通用名:Lucatumumab

純度:>95% by SDS-PAGE.

濃度:1mg/ml

Formulationicon:0.01M PBS, pH 7.4.

內(nèi)毒素:Please contact with the lab for this information.

別名:CHIR-12, 12, HCD122

靶點(diǎn);物種:Human CD40/TNFRSF5

種類:Homo sapiens

受體鑒定:IgG1-kappa

CAS: 903512-50-5

存儲(chǔ)條件:Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻(xiàn):

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. PMID: 22475052

Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. PMID: 24219359

Activity of the CD40 antagonistic antibody lucatumumab - insights from CLL-niche mimicking xenografts and fludarabine combinations. PMID: 26758550

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. PMID: 22861192

Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling. PMID: 31404613

Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. PMID: 24555495

Emerging immune targets for the treatment of multiple myeloma. PMID: 29421983

Emerging antibodies for the treatment of multiple myeloma. PMID: 27195659

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). PMID: 29572070

Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. PMID: 25249370

Interfering with CD40 ligation: a sensitive matter in chronic lymphocytic leukemia. PMID: 22563816

聯(lián)系方式
手機(jī):18162686757
微信掃一掃
正镶白旗| 高密市| 海城市| 肃北| 鄢陵县| 久治县| 文登市| 金寨县| 探索| 洪泽县| 广南县| 陵水| 葵青区| 象山县| 多伦县| 来凤县| 沾益县| 西平县| 衡水市| 贞丰县| 大兴区| 伊宁市| 清原| 新竹市| 三门县| 五大连池市| 南充市| 从江县| 龙南县| 缙云县| 内黄县| 武平县| 竹山县| 珠海市| 潍坊市| 岢岚县| 信宜市| 永济市| 淅川县| 阳东县| 大邑县|